Immune Tolerance Network, San Francisco, CA 94107, USA.
Clin Exp Immunol. 2010 May;160(2):176-84. doi: 10.1111/j.1365-2249.2010.04153.x.
Like many other complex human disorders of unknown aetiology, autoimmune-mediated type 1 diabetes may ultimately be controlled via a therapeutic approach that combines multiple agents, each with differing modes of action. The numerous advantages of such a strategy include the ability to minimize toxicities and realize synergies to enhance and prolong efficacy. The recognition that combinations might offer far-reaching benefits, at a time when few single agents have yet proved themselves in well-powered trials, represents a significant challenge to our ability to conceive and implement rational treatment designs. As a first step in this process, the Immune Tolerance Network, in collaboration with the Juvenile Diabetes Research Foundation, convened a Type 1 Diabetes Combination Therapy Assessment Group, the recommendations of which are discussed in this Perspective paper.
与许多其他病因不明的复杂人类疾病一样，自身免疫介导的 1 型糖尿病最终可能通过一种联合治疗方法得到控制，这种方法结合了多种具有不同作用机制的药物。这种策略有许多优点，包括能够最大限度地减少毒性并实现协同作用，以增强和延长疗效。在很少有单一药物在大型试验中证明有效的情况下，认识到联合治疗可能带来深远的益处，这对我们构思和实施合理治疗方案的能力构成了重大挑战。作为这一过程的第一步，免疫耐受网络与青少年糖尿病研究基金会合作，召集了 1 型糖尿病联合治疗评估小组，本文讨论了该小组的建议。
